Gerinnungsstörung bei Zirrhose

Patienten mit terminaler Leberinsuffizienz zeigen im klassischen Labor (Quick, aPTT, Fibrinogen) pathologische Werte, was auf eine Blutungsneigung hinweist. Gemäß aktuellen Daten neigen diese Patienten eher zu Thrombosen als zu Blutungen. Viskoelastische Tests, wie ROTEM oder TEG, liefern eine dynamische Bewertung der Gerinnselbildung im Vollblut – bei der Therapie von Gerinnungsproblemen ein deutlicher Vorteil gegenüber dem Standardlabor.

Kernaussagen

• Patienten mit Leberzirrhose neigen stärker zu Thrombosen als zu Blutungen, sodass eine Thromboseprophylaxe bei Immobilisation erforderlich ist, auch wenn die SLT pathologische Ergebnisse liefern.

• Im Falle einer Pfortaderthrombose können niedermolekulare Heparine eingesetzt werden. Zu den DOAC gibt es aktuell nur wenige Erfahrungsberichte und es muss abgewartet werden, ob sie gegenüber NMH oder Phenprocoumon einen relevanten Vorteil haben.

• Die Gerinnungsdiagnostik und die Therapie sollten anhand von VET (ROTEM oder TEG) erfolgen.

• Das Risiko einer Blutung korreliert nicht mit den Werten der SLT, sondern mit dem portalen Druck. Daher sollten eine Volumentherapie und vor allem der prophylaktische Einsatz von FFP auf jeden Fall unterbleiben.

Schlüsselwörter

Leberinsuffizienz - Hämostase - Blutungsmanagement - Thromboseprophylaxe - viskoelastische Testverfahren

Publikationsverlauf

Artikel online veröffentlicht:
08. März 2021

• Literatur

• 1 Hoffman M, Monroe DM. A cell-based model of hemostasis. Thromb Haemost 2001; 85: 958-965
• 2 Saner FH, Bezinover D. Assessment and management of coagulopathy in critically-ill patients with liver failure. Curr Opin Crit Care 2019; 25: 179-186 doi:10.1097/MCC.0000000000000591
• 3 Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med 2011; 365: 147-156 doi:10.1056/NEJMra1011170
• 4 Giannini EG, Savarino V. Thrombocytopenia in liver disease. Curr Opin Hematol 2008; 15: 473-480 doi:10.1097/MOH.0b013e32830a9746
• 5 Lisman T, Bongers TN, Adelmeijer J. et al. Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006; 44: 53-61 doi:10.1002/hep.21231
• 6 Gerbes AL, Gulberg V, Sauerbruch T. et al. [German S3-guideline “Ascites, spontaneous bacterial peritonitis, hepatorenal syndrome”]. Z Gastroenterol 2011; 49: 749-779 doi:10.1055/s-0031-1273405
• 7 de Boer MT, Christensen MC, Asmussen M. et al. The impact of intraoperative transfusion of platelets and red blood cells on survival after liver transplantation. Anesth Analg 2008; 106: 32-44 doi:10.1213/01.ane.0000289638.26666.ed
• 8 Gorlinger K, Dirkmann D, Solomon C. et al. Fast interpretation of thromboelastometry in non-cardiac surgery: reliability in patients with hypo-, normo-, and hypercoagulability. Br J Anaesth 2013; 110: 222-230 doi:10.1093/bja/aes374
• 9 Deppe AC, Weber C, Zimmermann J. et al. Point-of-care thromboelastography/thromboelastometry-based coagulation management in cardiac surgery: a meta-analysis of 8332 patients. J Surg Res 2016; 203: 424-433 doi:10.1016/j.jss.2016.03.008
• 10 Wikkelso A, Wetterslev J, Moller AM. et al. Thromboelastography (TEG) or thromboelastometry (ROTEM) to monitor haemostatic treatment versus usual care in adults or children with bleeding. Cochrane Database Syst Rev 2016; (08) CD007871
• 11 Bonnet A, Gilquin N, Steer N. et al. The use of a thromboelastometry-based algorithm reduces the need for blood product transfusion during orthotopic liver transplantation: A randomised controlled study. Eur J Anaesthesiol 2019; 36: 825-833 doi:10.1097/EJA.0000000000001084
• 12 De Pietri L, Bianchini M, Montalti R. et al. Thrombelastography-guided blood product use before invasive procedures in cirrhosis with severe coagulopathy: A randomized, controlled trial. Hepatology 2016; 63: 566-573 doi:10.1002/hep.28148
• 13 Tripodi A, Salerno F, Chantarangkul V. et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 2005; 41: 553-558 doi:10.1002/hep.20569
• 14 Stanworth SJ, Grant-Casey J, Lowe D. et al. The use of fresh-frozen plasma in England: high levels of inappropriate use in adults and children. Transfusion 2011; 51: 62-70 doi:10.1111/j.1537-2995.2010.02798.x
• 15 Giannini EG, Trevisani F. Improving survival of cirrhosis patients with hepatocellular carcinoma through application of standard of care. Hepatology 2014; 60: 1446-1447 doi:10.1002/hep.27008
• 16 Saner FH, Abeysundara L, Hartmann M. et al. Rational approach to transfusion in liver transplantation. Minerva Anestesiol 2018; 84: 378-388 doi:10.23736/S0375-9393.17.12231-5
• 17 Sorensen B, Spahn DR, Innerhofer P. et al. Clinical review: Prothrombin complex concentrates – evaluation of safety and thrombogenicity. Crit Care 2011; 15: 201 doi:10.1186/cc9311
• 18 Abuelkasem E, Hasan S, Mazzeffi MA. et al. Reduced requirement for prothrombin complex concentrate for the restoration of thrombin generation in plasma from liver transplant recipients. Anesth Analg 2017; 125: 609-615 doi:10.1213/ANE.0000000000002106
• 19 Sabate A, Gutierrez R, Beltran J. et al. Impact of preemptive fibrinogen concentrate on transfusion requirements in liver transplantation: a multicenter, randomized, double-blind, placebo-controlled trial. Am J Transplant 2016; 16: 2421-2429 doi:10.1111/ajt.13752
• 20 Bezinover D, Dirkmann D, Findlay J. et al. Perioperative coagulation management in liver transplant recipients. Transplantation 2018; 102: 578-592 doi:10.1097/TP.0000000000002092
• 21 Simpson E, Lin Y, Stanworth S. et al. Recombinant factor VII a for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database Syst Rev 2012; (03) CD005011
• 22 Kozek-Langenecker SA, Ahmed AB, Afshari A. et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology: First update 2016. Eur J Anaesthesiol 2017; 34: 332-395 doi:10.1097/EJA.0000000000000630
• 23 Kirchner C, Dirkmann D, Treckmann JW. et al. Coagulation management with factor concentrates in liver transplantation: a single-center experience. Transfusion 2014; 54: 2760-2768 doi:10.1111/trf.12707
• 24 Saner FH, Gieseler RK, Akiz H. et al. Delicate balance of bleeding and thrombosis in end-stage liver disease and liver transplantation. Digestion 2013; 88: 135-144 doi:10.1159/000354400
• 25 Lau JYW, Yu Y, Tang RSY. et al. Timing of endoscopy for acute upper gastrointestinal bleeding. N Engl J Med 2020; 382: 1299-1308 doi:10.1056/NEJMoa1912484
• 26 Villa E, Camma C, Marietta M. et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 2012; 143: 1253-1260 doi:10.1053/j.gastro.2012.07.018
• 27 Bechmann LP, Sichau M, Wichert M. et al. Low-molecular-weight heparin in patients with advanced cirrhosis. Liver Int 2011; 31: 75-82 doi:10.1111/j.1478-3231.2010.02358.x
• 28 Intagliata NM, Caldwell SH, Porte RJ. et al. Prediction of bleeding in cirrhosis patients: Is the forecast any clearer?. Hepatology 2016; 64: 989-990 doi:10.1002/hep.28426
• 29 Finks SW, Rogers KC. Idarucizumab (Praxbind): The first reversal agent for a direct oral anticoagulant. Am J Med 2017; 130: e195-e197 doi:10.1016/j.amjmed.2016.11.029
• 30 Intagliata NM, Maitland H, Pellitier S. et al. Reversal of direct oral anticoagulants for liver transplantation in cirrhosis: A step forward. Liver Transpl 2017; 23: 396-397 doi:10.1002/lt.24708
• 31 Rogers KC, Finks SW. A new option for reversing the anticoagulant effect of factor Xa inhibitors: andexanet alfa (ANDEXXA). Am J Med 2019; 132: 38-41 doi:10.1016/j.amjmed.2018.06.028
• 32 Grottke O, Schulman S. Four-factor prothrombin complex concentrate for the management of patients receiving direct oral activated factor X inhibitors. Anesthesiology 2019; 131: 1153-1165 doi:10.1097/ALN.0000000000002910
• 33 Mangia A, Villani MR, Cappucci G. et al. Causes of portal venous thrombosis in cirrhotic patients: the role of genetic and acquired factors. Eur J Gastroenterol Hepatol 2005; 17: 745-751 doi:10.1097/00042737-200507000-00009
• 34 Werner KT, Sando S, Carey EJ. et al. Portal vein thrombosis in patients with end stage liver disease awaiting liver transplantation: outcome of anticoagulation. Dig Dis Sci 2013; 58: 1776-1780 doi:10.1007/s10620-012-2548-y
• 35 Senzolo M, Sartori TM, Rossetto V. et al. Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis. Liver Int 2012; 32: 919-927 doi:10.1111/j.1478-3231.2012.02785.x
• 36 Francoz C, Belghiti J, Vilgrain V. et al. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut 2005; 54: 691-697 doi:10.1136/gut.2004.042796
• 37 Delgado MG, Seijo S, Yepes I. et al. Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. Clin Gastroenterol Hepatol 2012; 10: 776-783 doi:10.1016/j.cgh.2012.01.012
• 38 Cui SB, Shu RH, Yan SP. et al. Efficacy and safety of anticoagulation therapy with different doses of enoxaparin for portal vein thrombosis in cirrhotic patients with hepatitis B. Eur J Gastroenterol Hepatol 2015; 27: 914-919 doi:10.1097/MEG.0000000000000351
• 39 Chen H, Liu L, Qi X. et al. Efficacy and safety of anticoagulation in more advanced portal vein thrombosis in patients with liver cirrhosis. Eur J Gastroenterol Hepatol 2016; 28: 82-89 doi:10.1097/MEG.0000000000000482
• 40 Amitrano L, Guardascione MA, Menchise A. et al. Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis. J Clin Gastroenterol 2010; 44: 448-451 doi:10.1097/MCG.0b013e3181b3ab44